Mariana Castanheira

List of Publications by Year in Descending Order

290 papers	13,201 citations	61 h-index	100 g-index
301 ext. papers	15,433 ext. citations	5.5 avg, IF	6.88 L-index

#	Paper	IF	Citations
290	Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020).. *European Journal of Clinical Microbiology and Infectious Diseases*, **2022**, 41, 477	5.3	2
289	Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program.. *Microbiology Spectrum*, **2022**, e0271221	8.9	3
288	Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020).. *European Journal of Clinical Microbiology and Infectious Diseases*, **2022**, 1	5.3	1
287	Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).. *Journal of Clinical Microbiology*, **2022**, e0244921	9.7	0
286	Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing.. *Diagnostic Microbiology and Infectious Disease*, **2022**, 103, 115673	2.9	0
285	Elderly versus nonelderly patients with invasive fungal infections: species distribution and antifungal resistance, SENTRY antifungal surveillance program 2017-2019.. *Diagnostic Microbiology and Infectious Disease*, **2021**, 102, 115627	2.9	0
284	Activity of Oritavancin Against Gram-positive Pathogens Causing Bloodstream Infections in the United States Over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019). *Antimicrobial Agents and Chemotherapy*, **2021**, AAC0166721	5.9	2
283	Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. *International Journal of Infectious Diseases*, **2021**, 113, 279-281	10.5	1
282	Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020. *European Journal of Clinical Microbiology and Infectious Diseases*, **2021**, 1	5.3	2
281	Activity of KBP-7072 (a novel aminomethylcycline) and comparators against 1,057 geographically diverse recent clinical isolates from the SENTRY Surveillace Program (2019). *Antimicrobial Agents and Chemotherapy*, **2021**, AAC0139721	5.9	0
280	In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes. *Journal of Antimicrobial Chemotherapy*, **2021**,	5.1	1
279	Evaluation of Synergistic Activity of Isavuconazole or Voriconazole plus Anidulafungin and the Occurrence and Genetic Characterization of Candida auris Detected in a Surveillance Program. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	9
278	Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP). *International Journal of Antimicrobial Agents*, **2021**, 57, 106278	14.3	2
277	Activity of meropenem/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region. *Journal of Global Antimicrobial Resistance*, **2021**, 24, 190-197	3.4	4
276	Comparative activity of posaconazole and systemic azole agents against clinical isolates of filamentous fungi from a global surveillance programme. *JAC-Antimicrobial Resistance*, **2021**, 3, dlab088	2.9	2
275	Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	4
274	Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011-2019). *Journal of Antibiotics*, **2021**, 74, 519-527	3.7	3

273	Isavuconazole nonwildtype Aspergillus fumigatus isolates from a global surveillance study display alterations in multiple genes involved in the ergosterol biosynthesis pathway not previously associated with resistance to other azoles. *Mycoses*, **2021**, 64, 1279-1290	5.2	2
272	Activity of plazomicin against carbapenem-intermediate or -resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 2061-2070	5.1	0
271	Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against from cystic fibrosis patients. *JAC-Antimicrobial Resistance*, **2021**, 3, dlab126	2.9	4
270	Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: results from the SENTRY Antimicrobial Surveillance Program (2016-19). *JAC-Antimicrobial Resistance*, **2021**, 3, dlab117	2.9	2
269	Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19). *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 2600-2605	5.1	3
268	Global molecular epidemiology of carbapenem-resistant Escherichia coli (2002-2017). *European Journal of Clinical Microbiology and Infectious Diseases*, **2021**, 1	5.3	3
267	Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against and Isolates from United States Medical Centers in 2016-2018. *Microbial Drug Resistance*, **2021**, 27, 342-349	2.9	10
266	Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 659-666	5.1	12
265	Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 2833-2838	5.1	4
264	Molecular Characterization of Baseline and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	3
263	Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection. *JAC-Antimicrobial Resistance*, **2021**, 3, dlab092	2.9	44
262	Characterization of and species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agents. *JAC-Antimicrobial Resistance*, **2021**, 3, dlab136	2.9	1
261	Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 3125-3134	5.1	8
260	Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0264620	5.9	6
259	Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0126421	5.9	2
258	Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019). *Journal of Global Antimicrobial Resistance*, **2021**, 26, 117-127	3.4	4
257	Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. *International Journal of Antimicrobial Agents*, **2021**, 58, 106439	14.3	11
256	Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018-2020). *Diagnostic Microbiology and Infectious Disease*, **2021**, 102, 115557	2.9	4

255	In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years. *Diagnostic Microbiology and Infectious Disease*, **2021**, 101, 115473	2.9	3
254	Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms. *Diagnostic Microbiology and Infectious Disease*, **2020**, 97, 115054	2.9	2
253	Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and Elactamases with ceftazidime hydrolytic activity lead to elevated MIC values. *International Journal of Antimicrobial Agents*, **2020**, 56, 106011	14.3	9
252	Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	8
251	Media for colistin susceptibility testing does not improve the detection of Klebsiella pneumoniae isolates carrying MgrB disruption and other mutation driven colistin resistance mechanisms. *Diagnostic Microbiology and Infectious Disease*, **2020**, 98, 115077	2.9	3
250	Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): therapeutic options for multidrug-resistant bacteria. *Diagnostic Microbiology and Infectious Disease*, **2020**, 98, 115108	2.9	10
249	Bacterial and fungal pathogens isolated from patients with bloodstream infection: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012-2017). *Diagnostic Microbiology and Infectious Disease*, **2020**, 97, 115016	2.9	9
248	In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018. *Diagnostic Microbiology and Infectious Disease* , **2020**, 97, 115007	2.9	7
247	Meropenem-Vaborbactam Activity against Carbapenem-Resistant Isolates Collected in U.S. Hospitals during 2016 to 2018. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	20
246	Activity of Plazomicin Tested against Isolates Collected from U.S. Hospitals in 2016-2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	9
245	Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America. *International Journal of Infectious Diseases*, **2020**, 91, 32-37	10.5	10
244	Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	11
243	Activity Analysis of a New Polymyxin, SPR741, Tested in Combination with Antimicrobial Agents against a Challenge Set of , Including Molecularly Characterized Strains. *Antimicrobial Agents and Chemotherapy*, **2020**, 65,	5.9	2
242	Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region. *Antimicrobial Agents and Chemotherapy*,	5.9	14
241	Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	5
240	Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). *Diagnostic Microbiology and Infectious Disease*, **2020**, 96, 114833	2.9	20
239	Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination. *International Journal of Antimicrobial Agents*, **2020**, 55, 105799	14.3	22
238	Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018). *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	20

237	Updated Prevalence of -Like Genes among and in the SENTRY Program and Characterization of Variant. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	9
236	In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions. *Diagnostic Microbiology and Infectious Disease*, **2019**, 94, 73-77	2.9	16
235	First reported human isolation of Staphylococcus delphini. *Diagnostic Microbiology and Infectious Disease*, **2019**, 94, 274-276	2.9	9
234	Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 2588-2595	5.1	15
233	Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	52
232	Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017). *Diagnostic Microbiology and Infectious Disease*, **2019**, 95, 114850	2.9	18
231	Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015). *Journal of Chemotherapy*, **2019**, 31, 188-194	2.3	15
230	Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum Lactamases from U.S. Hospitals. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	25
229	Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program. *Open Forum Infectious Diseases*, **2019**, 6, S23-S33	1	64
228	Application of Next-Generation Sequencing for Characterization of Surveillance and Clinical Trial Isolates: Analysis of the Distribution of lactamase Resistance Genes and Lineage Background in the United States. *Open Forum Infectious Diseases*, **2019**, 6, S69-S78	1	27
227	Characterization of Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against Lactamase Producers. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	14
226	Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Species From 1997-2016. *Open Forum Infectious Diseases*, **2019**, 6, S79-S94	1	227
225	Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016). *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1595-1606	5.1	24
224	Aminoglycoside-modifying enzyme and 16S ribosomal RNA methyltransferase genes among a global collection of Gram-negative isolates. *Journal of Global Antimicrobial Resistance*, **2019**, 16, 278-285	3.4	24
223	Antimicrobial Susceptibility of Complex and Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997-2016). *Open Forum Infectious Diseases*, **2019**, 6, S34-S46	1	72
222	Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	14
221	Analysis of Candida auris fungemia at a single facility in Kenya. *International Journal of Infectious Diseases*, **2019**, 85, 182-187	10.5	27
220	2115. Activity of a Long-Acting Echinocandin Rezafungin and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018. *Open Forum Infectious Diseases*, **2019**, 6, S716-S716	1	1

219	First Report of - and -Coharboring Species Isolated from a Pediatric Patient. *MSphere*, **2019**, 4,	5	33
218	677. Activity of Novel Lactamase Inhibitor QPX7728 Combined with Lactam Agents When Tested Against Carbapenem-Resistant Enterobacteriaceae (CRE) Isolates. *Open Forum Infectious Diseases*, **2019**, 6, S309-S309	1	3
217	Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Bacteremia and Abscess in a Liver Transplant Recipient. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	51
216	How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates. *Clinical Microbiology and Infection*, **2019**, 25, 681-687	9.5	42
215	Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers. *Diagnostic Microbiology and Infectious Disease*, **2019**, 94, 93-102	2.9	23
214	In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. *International Journal of Antimicrobial Agents*,	14.3	57
213	Molecular Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets. *International Journal of Antimicrobial Agents*, **2018**, 52, 287-292	14.3	18
212	ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 1880-1887	5.1	37
211	Fungemia Surveillance in Denmark Demonstrates Emergence of Non-albicans Candida Species and Higher Antifungal Usage and Resistance Rates than in Other Nations. *Journal of Clinical Microbiology*, **2018**, 56,	9.7	12
210	CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests. *Journal of Clinical Microbiology*, **2018**, 56,	9.7	187
209	Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016). *International Journal of Antimicrobial Agents*, **2018**, 51, 608-611	14.3	31
208	Determination of MIC and disk diffusion quality control guidelines for meropenem-vaborbactam, a novel carbapenem/boronic acid Lactamase inhibitor combination. *Diagnostic Microbiology and Infectious Disease*, **2018**, 90, 324-328	2.9	5
207	Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	33
206	Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16). *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 916-922	5.1	1
205	Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). *Diagnostic Microbiology and Infectious Disease*, **2018**, 91, 77-84	2.9	23
204	Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016. *Diagnostic*	2.9	54
203	Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014. *Diagnostic Microbiology and Infectious Disease*, **2018**, 91, 199-204	2.9	15
202	Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility. *Microbial Drug Resistance*, **2018**, 24, 563-577	2.9	39

201	Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	58
200	Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). *International Journal of Antimicrobial Agents*, **2018**, 51, 191-199	14.3	19
199	Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17). *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 3053-3059	5.1	33
198	Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	30
197	Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds. *Diagnostic Microbiology and Infectious Disease*, **2018**, 92, 43-45	2.9	1
196	Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2314-2322	5.1	50
195	Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	51
194	Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2400-2404	5.1	28
193	Postmarketing experience with Neutrolin (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients. *European Journal of Clinical Microbiology and Infectious Diseases*, **2018**, 37, 661-663	5.3	6
192	Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010-2016): concomitant analysis of oritavancin in vitro activity. *Journal of Chemotherapy*, **2018**, 30, 280-289	2.3	16
191	Analyses of a Ceftazidime-Avibactam-Resistant Isolate Carrying Reveals a Heterogenous Population and Reversible Genotype. *MSphere*, **2018**, 3,	5	16
190	Multidrug-resistant from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam. *Infection and Drug Resistance*, **2018**, 11, 1499-1510	4.2	15
189	Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	23
188	Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2244-2251	5.1	38
187	Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program. *Diagnostic Microbiology and Infectious Disease*, **2018**, 92, 158-163	2.9	24
186	Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014). *Diagnostic Microbiology and Infectious Disease*, **2017**, 87, 261-265	2.9	3
185	Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	33
184	Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	34

183	Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	19
182	Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	66
181	WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	52
180	Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014. *Pediatric Infectious Disease Journal*, **2017**, 36, 486-491	3.4	13
179	Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	54
178	Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	49
177	Epidemic Emergence in the United States of Escherichia coli Sequence Type 131-30 (ST131-30), 2000 to 2009. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	36
176	WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 1696-1703	5.1	68
175	Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 1386-1395	5.1	61
174	Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	28
173	Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations. *Diagnostic Microbiology and Infectious Disease*, **2017**, 88, 184-187	2.9	11
172	Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying Collected in U.S. Hospitals from 2012 to 2015. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	38
171	Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. *Journal of Global Antimicrobial Resistance*, **2017**, 8, 28-32	3.4	5
170	Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015). *Brazilian Journal of Infectious Diseases*, **2017**, 21, 627-637	2.8	25
169	The Pandemic 30 Subclone of Sequence Type 131 (ST131) as the Leading Cause of Multidrug-Resistant Infections in the United States (2011-2012). *Open Forum Infectious Diseases*, **2017**, 4, ofx089	1	52
168	Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	73
167	In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions. *Microbial Drug Resistance*, **2017**, 23, 718-726	2.9	7
166	CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program. *International Journal of Antimicrobial Agents*, **2017**, 50, 352-358	14.3	46

165	Case report of transient mcr-1-haboring Escherichia coli with concurrent Staphylococcus aureus bacteremia in Long Beach, California. *Diagnostic Microbiology and Infectious Disease*, **2017**, 89, 303-304	2.9	5
164	Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015). *Journal of Global Antimicrobial Resistance*, **2017**, 11, 4-7	3.4	9
163	Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	59
162	The application of in vitro surveillance data for antibacterial dose selection. *Current Opinion in Pharmacology*, **2017**, 36, 130-138	5.1	3
161	Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	116
160	Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. *Clinical Infectious Diseases*, **2017**, 64, 134-140	11.6	753
159	Enhanced activity of cefepime-tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride. *Diagnostic Microbiology and Infectious Disease*, **2017**, 89, 305-309	2.9	10
158	Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13). *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 276-8	5.1	18
157	Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis. *Medical Mycology*, **2016**, 54, 1-22	3.9	90
156	Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 5454-8	5.9	98
155	Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 3827-31	5.9	19
154	High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center. *Clinical Infectious Diseases*, **2016**, 63, 954-958	11.6	38
153	Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 2868-73	5.1	71
152	In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2537-41	5.9	25
151	Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2075-80	5.9	32
150	Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013). *Diagnostic Microbiology and Infectious Disease*, **2016**, 85, 200-4	2.9	82
149	Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata. *International Journal of Antimicrobial Agents*, **2016**, 47, 286-8	14.3	4
148	Klebsiella pneumoniae Isolate from a New York City Hospital Belonging to Sequence Type 258 and Carrying blaKPC-2 and blaVIM-4. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 1924-7	5.9	11

147	Mechanisms of Resistance, Clonal Expansion, and Increasing Prevalence of Acinetobacter baumannii Strains Displaying Elevated Tigecycline MIC Values in Latin America. *Microbial Drug Resistance*, **2016**, 22, 253-8	2.9	10
146	Detection of mcr-1 among Escherichia coli Clinical Isolates Collected Worldwide as Part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 5623-4	5.9	86
145	In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013). *International Journal of Antimicrobial Agents*, **2016**, 47, 495-9	14.3	16
144	Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014). *International Journal of Antimicrobial Agents*, **2016**, 48, 144-50	14.3	38
143	Changes in the Frequencies of β-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β-Lactamase-Producing Isolates. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 4770-7	5.9	43
142	Ceftaroline activity tested against viridans group streptococci from US hospitals. *Diagnostic Microbiology and Infectious Disease*, **2016**, 84, 232-5	2.9	4
141	Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013). *Diagnostic Microbiology and Infectious Disease*, **2016**, 85, 352-355	2.9	19
140	Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014. *Surgical Infections*, **2016**, 17, 473-8	2	10
139	Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 4355-60	5.9	20
138	Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 3453-3458	5.1	50
137	In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012. *Mycoses*, **2015**, 58, 209-14	5.2	27
136	Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014). *Diagnostic Microbiology and Infectious Disease*, **2015**, 83, 389-94	2.9	21
135	Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. *Diagnostic Microbiology and Infectious Disease*, **2015**, 82, 78-84	2.9	16
134	Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013). *Diagnostic Microbiology and Infectious Disease*, **2015**, 83, 183-6	2.9	47
133	Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012). *Journal of Antibiotics*, **2015**, 68, 556-61	3.7	42
132	In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species. *Diagnostic Microbiology and Infectious Disease*, **2015**, 81, 259-63	2.9	50
131	Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. *International Journal of Antimicrobial Agents*, **2015**, 46, 53-9	14.3	55
130	Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. *Diagnostic Microbiology and Infectious Disease*, **2015**, 82, 303-13	2.9	86

129	Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 3509-17	5.9	92
128	β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates. *Antimicrobial Agents and Chemotherapy*, **2015**, 60, 1328-35	5.9	22
127	Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 3656-9	5.9	65
126	Detection of NDM-1-producing Enterobacteriaceae in Romania: report of the SENTRY Antimicrobial Surveillance Program. *Journal of Medical Microbiology*, **2014**, 63, 483-484	3.2	3
125	Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 1804-14	5.1	135
124	Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 1684-92	5.9	116
123	Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria. *Journal of Clinical Microbiology*, **2014**, 52, 108-14	9.7	42
122	Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011. *Mycoses*, **2014**, 57, 602-11	5.2	67
121	Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria. *Journal of Clinical Microbiology*, **2014**, 52, 3223-9	9.7	41
120	Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 6844-50	5.9	93
119	Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. *International Journal of Antimicrobial Agents*, **2014**, 44, 320-6	14.3	58
118	Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 2713-22	5.1	114
117	Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. *Mycopathologia*, **2014**, 178, 1-9	2.9	34
116	Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel β-lactamases, GES-22 and	5.9	45
115	Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 833-8	5.9	147
114	Candidemia surveillance in Iowa: emergence of echinocandin resistance. *Diagnostic Microbiology and Infectious Disease*, **2014**, 79, 205-8	2.9	38
113	Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. *Diagnostic Microbiology and Infectious Disease*, **2014**, 79, 198-204	2.9	57
112	Regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians!. *Diagnostic Microbiology and Infectious Disease*, **2014**, 80, 91-2	2.9	

111	In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 3646-9	5.9	8
110	116. *Critical Care Medicine*, **2014**, 42, A1388	1.4	
109	Retrospective molecular analysis of DIM-1 metallo-lactamase discovered in Pseudomonas stutzeri from India in 2000. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 596-8	5.9	8
108	Reply: regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians!. *Diagnostic Microbiology and Infectious Disease*, **2014**,	2.9	
107	Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel. *Journal of Chemotherapy*, **2014**, 26, 202-10	2.3	11
106	Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying lactamases prevalent in the United States. *Microbial Drug Resistance*, **2014**, 20, 436-40	2.9	15
105	Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 6024-31	5.9	34
104	Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 577-80	5.9	59
103	Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. *Clinical Infectious Diseases*, **2014**, 59 Suppl 6, S367-73	11.6	55
102	Resistance surveillance program report for selected European nations (2011). *Diagnostic Microbiology and Infectious Disease*, **2014**, 78, 429-36	2.9	68
101	Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011). *Diagnostic Microbiology and Infectious Disease*, **2013**, 77, 258-66	2.9	22
100	Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011). *Brazilian Journal of Infectious Diseases*, **2013**, 17, 672-81	2.8	77
99	Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. *Journal of Clinical Microbiology*, **2013**, 51, 2571-81	9.7	174
98	Regional resistance surveillance program results for 12 Asia-Pacific nations (2011). *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 5721-6	5.9	60
97	Update on the prevalence and genetic characterization of NDM-1-producing Enterobacteriaceae in Indian hospitals during 2010. *Diagnostic Microbiology and Infectious Disease*, **2013**, 75, 210-3	2.9	19
96	Prevalence of lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 3012-20	5.9	85
95	Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: report from the 2007-2009 SENTRY Antimicrobial Surveillance Program. *Diagnostic Microbiology and Infectious Disease*, **2013**, 76, 356-60	2.9	48
94	Isolation of genetically unrelated bla(NDM-1)-positive Providencia rettgeri strains in Israel. *Journal of Clinical Microbiology*, **2013**, 51, 1642-3	9.7	20

93	Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. *Clinical Infectious Diseases*, **2013**, 56, 1724-32	11.6	530
92	IMP-33, a New IMP variant detected in Pseudomonas aeruginosa from Sicily. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 6401-3	5.9	5
91	Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 858-63	5.1	77
90	Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 2809-14	5.9	65
89	In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1065-8	5.9	67
88	Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs. *Journal of Clinical Microbiology*, **2013**, 51, 117-24	9.7	79
87	In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. *Journal of Clinical Microbiology*, **2013**, 51, 2608-16	9.7	66
86	Rapid expansion of KPC-2-producing Klebsiella pneumoniae isolates in two Texas hospitals due to clonal spread of ST258 and ST307 lineages. *Microbial Drug Resistance*, **2013**, 19, 295-7	2.9	45
85	Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 4134-8	5.9	34
84	Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae testing susceptible to cefepime by reference methods. *Journal of Clinical Microbiology*, **2013**, 51, 2388-90	9.7	6
83	Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme. *Mycopathologia*, **2012**, 174, 259-71	2.9	60
82	Evaluation of quinolone resistance-determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolones. *Diagnostic Microbiology and Infectious Disease*, **2012**, 72, 263-6	2.9	13
81	Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). *Diagnostic Microbiology and Infectious Disease*, **2012**, 73, 354-60	2.9	169
80	Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial. *Diagnostic Microbiology and Infectious Disease*, **2012**, 74, 73-4	2.9	2
79	Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 4779-85	5.9	64
78	Candida glabrata: Multidrug Resistance and Increased Virulence in a Major Opportunistic Fungal Pathogen. *Current Fungal Infection Reports*, **2012**, 6, 154-164	1.4	7
77	Advances in Antifungal Susceptibility Testing of Candida, 2010–2012. *Current Fungal Infection Reports*, **2012**, 6, 141-153	1.4	2
76	Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009. *Emerging Infectious Diseases*, **2012**, 18, 598-607	10.2	85

75	Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. *Journal of Clinical Microbiology*, **2012**, 50, 2040-6	9.7	98
74	Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 258-70	5.9	60
73	In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). *Clinical Infectious Diseases*, **2012**, 55 Suppl 3, S206-14	11.6	64
72	Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 352-7	5.9	68
71	Expansion of clonal complex 258 KPC-2-producing Klebsiella pneumoniae in Latin American hospitals: report of the SENTRY Antimicrobial Surveillance Program. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 1668-9; author reply 1670-1	5.9	30
70	Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 5875-82	5.9	36
69	Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. *Journal of Clinical Microbiology*, **2012**, 50, 1199-203	9.7	284
68	Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. *International Journal of Antimicrobial Agents*, **2011**, 37, 39-45	14.3	34
67	Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). *International Journal of Antimicrobial Agents*, **2011**, 38, 65-9	14.3	178
66	Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09). *Journal of Antimicrobial Chemotherapy*, **2011**, 66, 1409-11	5.1	59
65	Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). *Diagnostic Microbiology and Infectious Disease*, **2011**, 69, 45-50	2.9	90
64	In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method. *Diagnostic Microbiology and Infectious Disease*, **2011**, 71, 167-70	2.9	47
63	Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. *Diagnostic Microbiology and Infectious Disease*, **2011**, 71, 252-9	2.9	51
62	Molecular typing of antimicrobial-resistant Shiga-toxin-producing Escherichia coli strains (STEC) in Brazil. *Research in Microbiology*, **2011**, 162, 117-23	4	25
61	Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins. *Current Fungal Infection Reports*, **2011**, 5, 120-127	1.4	3
60	Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). *Journal of Clinical Microbiology*, **2011**, 49, 396-9	9.7	154
59	Characterization of global patterns and the genetics of fusidic acid resistance. *Clinical Infectious Diseases*, **2011**, 52 Suppl 7, S487-92	11.6	50
58	Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 1274-8	5.9	266

57	Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods. *Journal of Antimicrobial Chemotherapy*, **2011**, 66, 2581-4	5.1	38
56	In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States. *Clinical Infectious Diseases*, **2011**, 52 Suppl 7, S477-86	11.6	34
55	OXA-163, an OXA-48-related class D -lactamase with extended activity toward expanded-spectrum cephalosporins. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 2546-51	5.9	110
54	Comment on: role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo--lactamases. *Journal of Antimicrobial Chemotherapy*, **2011**, 66, 684-5; author reply 686	5.1	11
53	Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 561-6	5.9	172
52	Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. *Journal of Clinical Microbiology*, **2011**, 49, 3800-4	9.7	55
51	In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 5155-8	5.9	57
50	Candida glabrata mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibility. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 3947-9	5.9	23
49	Dissemination and genetic context analysis of bla(VIM-6) among Pseudomonas aeruginosa isolates in Asian-Pacific Nations. *Clinical Microbiology and Infection*, **2010**, 16, 186-9	9.5	11
48	Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. *Clinical Infectious Diseases*, **2010**, 51, 286-94	11.6	393
47	Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008). *Journal of Clinical Microbiology*, **2010**, 48, 2984-7	9.7	25
46	Clonal dissemination of Klebsiella pneumoniae carbapenemase KPC-3 in Long Beach, California. *Journal of Clinical Microbiology*, **2010**, 48, 623-5	9.7	15
45	Fixed-ratio combination testing of an echinocandin, anidulafungin, and an azole, voriconazole, against 1,467 Candida species isolates. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 4041-3	5.9	3
44	Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 3614-7	5.9	73
43	CEM-101 activity against Gram-positive organisms. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2182-7	5.9	32
42	First description of bla(CTX-M-14)- and bla(CTX-M-15)-producing Escherichia coli isolates in Brazil. *Microbial Drug Resistance*, **2010**, 16, 177-84	2.9	27
41	Performance of fusidic acid (CEM-102) susceptibility testing reagents: broth microdilution, disk diffusion, and Etest methods as applied to Staphylococcus aureus. *Journal of Clinical Microbiology*, **2010**, 48, 972-6	9.7	10
40	Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. *Microbial Drug Resistance*, **2010**, 16, 61-5	2.9	42

39	Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2655-9	5.9	102
38	Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 4009-11	5.9	9
37	Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. *International Journal of Antimicrobial Agents*, **2010**, 35, 282-7	14.3	23
36	Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. *International Journal of Antimicrobial Agents*, **2010**, 35, 537-43	14.3	41
35	Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). *Journal of Antimicrobial Chemotherapy*, **2010**, 65, 1353-8	5.1	77
34	CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. *Diagnostic Microbiology and Infectious Disease*, **2010**, 66, 393-401	2.9	43
33	Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). *Diagnostic Microbiology and Infectious Disease*, **2010**, 68, 278-83	2.9	115
32	The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). *Journal of Infection*, **2010**, 61, 476-83	18.9	28
31	Dissemination of a bla(VIM-2)-carrying integron among Enterobacteriaceae species in Mexico: report from the SENTRY Antimicrobial Surveillance Program. *Microbial Drug Resistance*, **2009**, 15, 33-5	2.9	19
30	First descriptions of blaKPC in Raoultella spp. (R. planticola and R. ornithinolytica): report from the SENTRY Antimicrobial Surveillance Program. *Journal of Clinical Microbiology*, **2009**, 47, 4129-30	9.7	81
29	TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. *Journal of Antimicrobial Chemotherapy*, **2009**, 63, 716-20	5.1	35
28	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 843-4	5.9	13
27	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 1225-7	5.9	53
26	Dissemination of bla(IMP-1)-carrying integron In86 among Klebsiella pneumoniae isolates harboring a new trimethoprim resistance gene dfr23. *Diagnostic Microbiology and Infectious Disease* , **2009**, 63, 87-91	2.9	21
25	Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. *Diagnostic Microbiology and Infectious Disease*, **2009**, 63, 426-33	2.9	54
24	Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. *Journal of Antimicrobial Chemotherapy*, **2009**, 63, 55-9	5.1	124
23	Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006). *Diagnostic Microbiology and Infectious Disease*, **2008**, 61, 235-9	2.9	34
22	United States resistance surveillance results for linezolid (LEADER Program for 2007). *Diagnostic Microbiology and Infectious Disease*, **2008**, 62, 416-26	2.9	69

21	First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 2244-6	5.9	178
20	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 570-3	5.9	127
19	Emergence and clonal dissemination of OXA-24- and OXA-58-producing Acinetobacter baumannii strains in Houston, Texas: report from the SENTRY Antimicrobial Surveillance Program. *Journal of Clinical Microbiology*, **2008**, 46, 3179-80	9.7	14
18	RmtD 16S RNA methylase in epidemiologically unrelated spm-1-producing Pseudomonas aeruginosa isolates from Brazil. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 1587-8; author reply 1588	5.9	14
17	Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007). *Microbial Drug Resistance*, **2008**, 14, 211-6	2.9	72
16	Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites. *Journal of Medical Microbiology*, **2008**, 57, 1529-1532	3.2	39
15	Detection of methyltransferases conferring high-level resistance to aminoglycosides in enterobacteriaceae from Europe, North America, and Latin America. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 1843-5	5.9	102
14	IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 2289-90	5.9	9
13	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 2905-8	5.9	27
12	Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. *Journal of Clinical Microbiology*, **2007**, 45, 544-7	9.7	224
11	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 2611-4	5.9	49
10	First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 1527-9	5.9	29
9	In71, an Enterobacter cloacae blaVIM-1-carrying integron related to In70.2 from Italian Pseudomonas aeruginosa isolates: a SENTRY Antimicrobial Surveillance Program report. *Microbial Drug Resistance*, **2007**, 13, 130-4	2.9	7
8	Carriage of methicillin-resistant Staphylococcus aureus in children in Brazil. *Diagnostic Microbiology and Infectious Disease*, **2007**, 57, 467-70	2.9	18
7	Changing antimicrobial susceptibility patterns among Streptococcus pneumoniae and Haemophilus influenzae from Brazil: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004). *Microbial Drug Resistance*, **2006**, 12, 91-8	2.9	8
6	Metalo-beta-lactamases. *Jornal Brasileiro De Patologia E Medicina Laboratorial*, **2006**, 42, 103-113	2.3	9
5	Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program. *International Journal of Antimicrobial Agents*, **2005**, 25, 57-61	14.3	75
4	Emergence of the extended-spectrum beta-lactamase GES-1 in a Pseudomonas aeruginosa strain from Brazil: report from the SENTRY antimicrobial surveillance program. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 2344-5	5.9	35

3	First isolation of bla(VIM-2) in Latin America: report from the SENTRY Antimicrobial Surveillance Program. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 1433-4	5.9	37
2	Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 4654-61	5.9	211
1	Typing and molecular characterization of Streptococcus pneumoniae with reduced susceptibility to cefotaxime isolated in Latin America. *Microbial Drug Resistance*, **2003**, 9, 345-51	2.9	6